Autologous tumor infiltrating lymphocytes (TILs)

BIOLOGICAL2 trials

Sponsors

University Health Network, Toronto, Suzhou BlueHorse Therapeutics Co., Ltd.

Conditions

Cervical CarcinomaMelanomaNon Small Cell Lung CancerPleural Mesothelioma

Phase 1

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

CompletedNCT02414945

University Health Network, TorontoPleural Mesothelioma

Start: 2015-05-15End: 2020-10-31Updated: 2023-01-10

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

RecruitingNCT05366478

Suzhou BlueHorse Therapeutics Co., Ltd.Cervical Carcinoma, Melanoma, Non Small Cell Lung Cancer

Start: 2022-05-30End: 2029-05-30Target: 15Updated: 2022-08-02

Related Papers

T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors

Journal of Translational Medicine2026-08-11

Tumor infiltrating lymphocytes (LM103 infusion) in solid tumors: A phase I trial evaluating clinical and immunological anti-tumor activity.

Journal of Clinical Oncology2026-05-27

Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report

International Journal of Women s Health2024-01-017 citations